Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Interest Income

Income earned on cash, deposits, and investments held by the company.

Profound Medical Corp.TSX: PRN.TO

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $370.82K fell 16.7% year over year, ahead of the -51.4% change in trailing-twelve-month interest income. Sequentially, it rose 128.3% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Interest income amounted to 6.6% of revenue in FY2025, down 6.8 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -16.7% holds above the trailing-twelve-month pace of -51.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$370.82K+128.3% QoQ
Last fiscal yearDec 2025
$1.09M-24.2% YoY
LTMMar 2026
$996.93K-51.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.7%——
1 year-24.2%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
1.09M USD
Year-over-year change
-24.2%
4-year CAGR
+51.8%

Interest Income vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -51.4% is the 5th highest of 6, against a peer median of -32.7%.
  • Interest income amounts to 5.3% of revenue for PRN.TO, versus a peer median of 0.1%.
PRN.TO Competitors
Interest Income for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$2.1M USD+137.0%+36.2%—
DR.TOMedical Facilities CorporationLTM Mar 2026$1.84M USD-32.7%-36.0%0.6%
PRN.TOProfound Medical Corp.LTM Mar 2026$996.93K USD-51.4%+0.9%5.3%
CRRX.TOCareRx CorporationLTM Mar 2026CA$180K CAD+83.7%-16.6%0.0%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$141K CAD-47.4%-27.2%0.1%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$87.08K USD-59.3%+24.1%0.2%
Peer median (excluding PRN.TO) —-32.7%-16.6%0.1%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.